Molecular Diagnosis of Systemic Autoinflammatory Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-18

Study Completion Date

2033-05-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Systemic autoinflammatory diseases (SAIDs) are a set of rare clinically and genetically heterogeneous conditions. The project proposes to identify novel genes and specific signatures in subgroups of patients with SAIDs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunome Project Consortium for Autoinflammatory Disorders

NCT03919110

Autoinflammatory Diseases, Hereditary

COMPLETED

Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases

NCT05383339

Autoimmune Diseases Vasculitis Autoinflammatory Disease

RECRUITING

Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases

NCT05251415

Lupus Erythematosus Scleroderma Myositis +2 more

RECRUITING

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort

NCT02890134

Systemic Autoimmune Diseases

COMPLETED

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:

NCT02890121

Systemic Autoimmune Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

SAIDs are characterized by long dormant periods with no or only minor clinical symptoms interrupted by febrile crises accompanied by serous and synovial membrane inflammation that spontaneously resolves. Over the last decades, more than 50 genes encoding key components of the innate immune system have been identified to be involved in the pathophysiology of SAIDs, with both germline and somatic mosaic variations. When disease-causing variations are identified, specific biotherapies are proposed depending on the involved gene and pathway. However, despite these scientific advances, most SAIDs (70%) are of unknown etiology, the diagnosis is made with significant delay, and no targeted therapy can be suggested. This project aims to generate specific understanding and develop strategies for SAID patients with unknown etiology. The investigators aim to advance our understanding of SAIDs pathophysiology, find the disease-causing gene variations and identify the involved cellular pathways that should accelerate correct diagnosis and personalize treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Disease Genetic Disease Somatic Mutation Molecular Sequence Variation Molecular Pathway Deregulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A patient presenting with a clinical and biological aseptic inflammatory syndrome associating one or more of the following signs: spontaneously resolving fever, abdominal (pain, diarrhea), locomotor (arthralgia, myalgia), thoracic (pain, pericarditis), cutaneous, sensory (uveitis, deafness), or renal (amyloidosis) involvement.